Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 14/20 | 0.64 |
| ▸ | VEGFA | P15692 | 12/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31135677 | 1.00 | EPAS1 (0.64) | EPAS1VEGFACYP3A4CYP2C9 | |
| SCHEMBL30241855 | 0.89 | VEGFA (0.58) | EPAS1VEGFACYP3A4CYP2C9 | |
| SCHEMBL24127652 | 0.89 | VEGFA (0.58) | EPAS1VEGFACYP3A4CYP2C9 | |
| SCHEMBL31135701 | 0.89 | VEGFA (0.63) | EPAS1VEGFACYP3A4CYP2C9 | |
| SCHEMBL21902846 | 0.89 | VEGFA (0.63) | EPAS1VEGFACYP3A4CYP2C9 | |
| SCHEMBL24086877 | 0.89 | VEGFA (0.63) | EPAS1VEGFACYP3A4CYP2C9 | |
| SCHEMBL31135648 | 0.89 | VEGFA (0.63) | EPAS1VEGFACYP3A4CYP2C9 | |
| SCHEMBL24127981 | 0.88 | EPAS1 (0.64) | EPAS1VEGFA | |
| SCHEMBL30241858 | 0.88 | EPAS1 (0.64) | EPAS1VEGFA | |
| SCHEMBL21902843 | 0.81 | VEGFA (0.62) | EPAS1VEGFACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380536-A1 | INDANE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| WO-2020081695-A1 | INDANE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380536-A1 | INDANE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | HIF1AN, HIF1A, NFE2L2 | EPAS1 20/4885VEGFA 1112/4885CYP3A4 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.